1767 Results for "

Antiproliferative

" in MedChemExpress (MCE) Product Catalog:

Products (1767)

Sort by :

Categories

By Targets

Species:

Tags:

Sources:

Hosts:

Reactivities:

Applications:

Isotypes:

Conjugations:

Clonalities:

Modifications:

Products

466

Deferoxamine mesylate

466 Publications Verification

Cat. No.: HY-B0988

CAS No.: 138-14-7

Synonyms: Desferrioxamine B mesylate; DFOM

Target:

Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

466

Deferoxamine

466 Publications Verification

Cat. No.: HY-B1625

CAS No.: 70-51-9

Synonyms: Deferoxamine B; Deferriferrioxamine B; Deferrioxamine

Target:

HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) Apoptosis Akt Autophagy

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

269

Palbociclib

269 Cited Publications

Cat. No.: HY-50767

CAS No.: 571190-30-2

Synonyms: PD 0332991

Target:

CDK

Research Areas:

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

269

Palbociclib monohydrochloride

269 Cited Publications

Cat. No.: HY-50767A

CAS No.: 827022-32-2

Synonyms: PD 0332991 monohydrochloride

Target:

CDK

Research Areas:

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

264

Palbociclib isethionate

264 Cited Publications

Cat. No.: HY-A0065

CAS No.: 827022-33-3

Synonyms: PD 0332991 isethionate

Target:

CDK

Research Areas:

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

247

Palbociclib hydrochloride

247 Cited Publications

Cat. No.: HY-50767C

CAS No.: 571189-11-2

Synonyms: PD-0332991 hydrochloride

Target:

CDK

Research Areas:

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Compare